Stockscreener 앱 받기
6.90
3.90%
-0.28
시장 영업 전:
6.75
-0.15
-2.17%
전일 마감가:
$7.18
열려 있는:
$6.88
하루 거래량:
2.14M
Relative Volume:
1.18
시가총액:
$474.53M
수익:
$161.10M
순이익/손실:
$-308.60M
주가수익비율:
-1.4775
EPS:
-4.67
순현금흐름:
$-259.90M
1주 성능:
-14.18%
1개월 성능:
-57.49%
6개월 성능:
-71.81%
1년 성능:
-82.12%
1일 변동 폭
$6.75
$7.03
1주일 범위
$6.75
$8.13
52주 변동 폭
$6.75
$39.40
Arvinas Inc Stock (ARVN) Company Profile
명칭
Arvinas Inc
전화
203-535-1456
주소
395 WINCHESTER AVE, NEW HAVEN, CT
ARVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
6.90 | 474.53M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-12 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-03-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2024-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-01 | 개시 | Goldman | Buy |
| 2023-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-11-20 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-10-23 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-01-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 개시 | Barclays | Overweight |
| 2022-06-21 | 개시 | Jefferies | Hold |
| 2022-05-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-04-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2022-01-19 | 개시 | Goldman | Buy |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-09 | 개시 | BofA Securities | Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-21 | 개시 | Truist | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-12-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-06-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Oppenheimer | Perform |
| 2019-12-19 | 개시 | H.C. Wainwright | Buy |
| 2019-11-25 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-25 | 개시 | Wedbush | Outperform |
| 2019-09-12 | 개시 | BMO Capital Markets | Outperform |
| 2019-08-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-22 | 개시 | Citigroup | Buy |
| 2018-10-22 | 개시 | Goldman | Neutral |
| 2018-10-22 | 개시 | Piper Jaffray | Overweight |
모두보기
Arvinas Inc 주식(ARVN)의 최신 뉴스
We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth - Yahoo Finance
Edmond DE Rothschild Holding S.A. Takes Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Update - MarketBeat
BIT Capital GmbH Has $5.05 Million Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas (NASDAQ:ARVN) Hits New 52-Week LowHere's What Happened - MarketBeat
Where are the Opportunities in (ARVN) - news.stocktradersdaily.com
Arvinas stock hits 52-week low at $7.91 amid market challenges - Investing.com India
Arvinas stock hits 52-week low at $7.91 amid market challenges By Investing.com - Investing.com South Africa
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases - GlobeNewswire
Groundbreaking First Human Data: New PROTAC Drug Takes Aim at Parkinson's Disease - Stock Titan
Arvinas (NASDAQ:ARVN) Shares Down 5.1%Time to Sell? - MarketBeat
Arvinas FY2025 EPS Forecast Increased by Cantor Fitzgerald - MarketBeat
Noah Berkowitz Sells 8,658 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock - MarketBeat
Arvinas (NASDAQ:ARVN) Trading Up 4%Here's Why - MarketBeat
Wedbush Brokers Raise Earnings Estimates for Arvinas - MarketBeat
Wedbush Has Positive Outlook for Arvinas Q1 Earnings - MarketBeat
Arvinas chief medical officer sells $74,372 in common stock By Investing.com - Investing.com South Africa
Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance
Arvinas chief medical officer sells $74,372 in common stock - Investing.com India
Arvinas Chief Medical Officer Sells Shares to Cover Tax Obligations - TradingView
(ARVN) Technical Pivots with Risk Controls - Stock Traders Daily
Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds? - Yahoo Finance
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook By Investing.com - Investing.com Australia
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook - Investing.com
Arvinas (NASDAQ:ARVN) Price Target Cut to $12.00 by Analysts at Morgan Stanley - MarketBeat
Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance
The Goldman Sachs Group Downgrades Arvinas (NASDAQ:ARVN) to Neutral - MarketBeat
Arvinas (NASDAQ:ARVN) Given New $32.00 Price Target at Guggenheim - MarketBeat
Arvinas (NASDAQ:ARVN) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Bank of America Issues Pessimistic Forecast for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Arvinas (NASDAQ:ARVN) Hits New 1-Year LowHere's What Happened - MarketBeat
Oppenheimer Downgrades Arvinas (NASDAQ:ARVN) to Market Perform - MarketBeat
Arvinas' (ARVN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints - MSN
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Arvinas Inc (ARVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):